期刊文献+

MALDI-TOF质谱法检测人血清中沙林-丁酰胆碱酯酶加合物

Detection of Sarin-Butyrylcholinesterase Adduct in Human Serum by MALDI-TOF Mass Spectrometry
下载PDF
导出
摘要 对生物医学样品进行化学毒剂分析检测是禁止化学武器组织(OPCW)核查小组在毒剂指称使用调查中收集事实的方法之一。丁酰胆碱酯酶(BChE)作为有机磷毒剂在体内的作用靶点,是有机磷毒剂染毒检测的最佳生物指示物之一。利用亲和固相萃取(SPE)技术进一步发展了样品预处理方法,建立了血液样品中染毒BChE的分析方法;利用胰蛋白酶酶解方法,采用基质辅助激光解吸/电离飞行时间质谱(MALDI-TOFMS)比较了血液中BChE在沙林染毒前后的肽指纹谱变化。该方法灵敏度高、快速简便,可用于OPCW生物医学样品中毒剂暴露染毒的追溯性检测。 The analysis of biomedical samples is one part of the verification programs of OPCW (Organization for the Prohibition of Chemical Weapons), and the results would be used as evidence in case of allegations of chemical agents use. The organophosphorus nerve agents could covalently conjugate with human butyrylcholinesterase (BChE), which is one of the most important biomarkers to verify an exposure to nerve agents. In this paper, the affinity SPE technology was employed as pretreatment method on the case of the detection of serum samples. The difference of peptide mass fingerprints between BChE and sarin- BChE was compared by matrix-assisted laser desorption/ionization time-of-flight mass spec- trometry (MALDI-TOF MS) combined with trypsin digest, and the modified tryptic pep- tide by satin ([M+H]+ 3 048. 411 u) was found. The unmodified and modified fragmentswere also verified by tandem mass spectrometry, and the modified site could be attributed to Ser198. The method of verification of human plasma exposure to sarin can be used to track other organophosphorus agents successfully.
出处 《质谱学报》 EI CAS CSCD 北大核心 2013年第3期129-136,共8页 Journal of Chinese Mass Spectrometry Society
关键词 生物医学样品 有机磷毒剂 丁酰胆碱酯酶 基质辅助激光解吸 电离飞行时间质谱(MALDI-TOF MS) biomedical samples organophosphorus nerve agents butyrylcholinesterase matrix-assisted laser desorption/ionization time-of-{light mass spectrometry (MALDI-T()FMS)
  • 相关文献

参考文献20

  • 1Report of the specialists appointed by the secretar-y-general to investigate allegations by the Islamic Republic of Iran concerning the use of chemical weapons. UN document S/16, 433 of 26 March 1984.
  • 2OKUMURA T, TAKASU N, ISHIMATSU S, et al. Report on 640 victims of the Tokyo subway sarin attack[J]. Ann Emerg Med, 1996, 28 (2): 129-135.
  • 3Van der SCHANS M J, FIDDER A, Van OEV- EREN D, et al. Verification of exposure to eho- linesterase inhibitors: Generic detection of OPCW Schedule 1 nerve agent adducts to human butyryl- cholinesterase[J]. J Anal Toxicol, 2008, 32(1): 125-130.
  • 4BLACK R M, READ R W. Biological markers of exposure to organophosphorus nerve agents[J].Arch Toxicol, 2013, 87(3): 421-437.
  • 5HOld.AND K E, SOLANO M I, JOHNSON R C, et al. Modifications to the organophosphorus nerve agent-protein adduct refluoridation method for retrospective analysis of nerve agent exposures [J]. J Anal Toxicol, 2008, 32: 116-124.
  • 6FIDDER A, HUI.ST A G, NOORT D, et al. Re- trospective detection of exposure to organophos- phorus anti-cholinesterases: Mass spectrometric a- nalysis of phosphytated human butyrylcholinester- ase[J]. Chem Res Toxicol, 2002, 15: 582-590.
  • 7DOORN J A, SCHALL M, GAGE D A, et al. Identification of butyrylcholinesterase adducts af- ter inhibition with isomalathion using mass spec- trometry: Difference in mechanism between (1R)- and ( 1S)-stereoisomers[J]. Toxicol Appl Phar- macol, 2001, 176:73 80.
  • 8I.I H, RICORDEL I, TONG L, et al. Ected by mass spectrometry of butyrylcholinesterase adduct in human serum [J]. J Anal Toxicol, 2009, 29 (2) : 149 155.
  • 9GRUNWALD J, MARCUS D, PAPIER Y, et al. Large-scale purification and long-term stability of human butyrylcholinesterase: A potential bioseav- enger drug [J ]. J Biochem Biophys Methods, 1997, 34: 123-135.
  • 10MASSON P, LOCKRIDGE O. Butyrylcholinest- erase for protection from organophosphorus poi- sons; catalytic complexities and hysteretic behav- ior[J] Arch Biochem Biophys, 2010, 494 (2) : 107. doi:10. 1016/j. abb. 2009.12. 005.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部